Document is current
Any future updates will be listed below
-
Authors
Schnorr, Isabel
Andreas, Stefanie
Schumann, Linnea
Hahn, Svenja
Vehreschild, Jörg Janne
Maier, Daniel
-
Funding
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
- License Information
-
More Information
Article History
Received: 2 December 2024
Accepted: 2 April 2025
First Online: 10 April 2025
Declarations
:
: Stefanie Andreas (SA) owns stock in HAVN Life Sciences, Heidelberg Pharma AG and Pfizer. Linnea Schumann (LS) received travel compensation from IQVIA. Jörg Janne Vehreschild (JV) has personal fees from Merck/MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), University Hospital Freiburg/Congress and Communication, Academy for Infectious Medicine, University Manchester, German Society for Infectious Diseases (DGI), Ärztekammer Nordrhein, University Hospital Aachen, Back Bay Strategies, German Society for Internal Medicine (DGIM), Shionogi, Molecular Health, Netzwerk Universitätsmedizin, Janssen, NordForsk, Biontech, APOGEPHA and grants from Merck/MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), German Federal Ministry of Education and Research (BMBF), Deutsches Zentrum für Luft- und Raumfahrt (DLR), University of Bristol, Rigshospitalet Copenhagen. Daniel Maier (DM) received speaker honoraria from Free University Berlin and travel compensation from IQVIA.
: The project was a spin-off of a project approved by the ethics committee of the department of medicine of the Goethe University Frankfurt (Project-Number: UCT-28-2021). As no patient-relatable data was involved no separate approval was required.
